Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- befree-2016 importedOn "2016-02-19" NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_assertion wasGeneratedBy ECO_0000203 NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_assertion wasDerivedFrom befree-2016 NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_assertion SIO_000772 17992582 NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_assertion evidence source_evidence_literature NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.
- NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_assertion description "[Ultimately, molecularly based designer pharmaceuticals may emerge from this research, such as the case of trastuzumab (Herceptin) in HER-2/neu positive breast cancer, and imatinib (Gleevec) in chronic myelocytic leukemia and gastrointestinal stromal tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP639626.RAh01vztZfCLNLV_4j8YjcFDc8QkDxLjLKoxlgY6Xu33k130_provenance.